Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Pharm-ANS
Y2S1B2
| ANS drugs | Features |
|---|---|
| Autonomic Nervous System | Enteric (semiautonomous), Parasympathetic (CN III, VII, IX, X and S2-S4), Sympathetic (T1-12, L1-L5) |
| Cholinomimetic (cholinergic) Drug Breakdown: Direct Acting | Muscarinic (choline esters, alkaloids) and Nicotinic |
| Cholinomimetic (Cholinergic) Drug Breakdown: Indirect Acting | Edrophonium (short-acting), Carbamates (intermed-long acting), Organophosphates (very long-acting) |
| Adrenergic Agonists: Adrenoceptors | alpha1, alpha2, beta1, beta2 |
| Adrenoceptors: alpha1 | vasoconstriction, inc peripheral resistance, inc BP, inc closure of internal bladder sphincter, mydriasis |
| Adrenoceptors: alpha2 | inhibition of NorEpi release, inhibition of insulin release |
| Adrenoceptors: beta1 | tachycardia, inc lipolysis, inc myocardial contractility, inc release of renin |
| Adrenoceptors: beta2 | vasodilation, slight dec peripheral resistance, bronchodilation, inc release of glucagon, relaxed uterine smooth muscle |
| ANS Direct-acting drugs | muscarine, carbachol, bethenachol, pilocarpine, nicotine, succinylcholine |
| ANS Indirect-acting drugs | echotiphate (irreversible), edrophonium, neostigmine, pyridostigmine, physostigmine, parathion, malathion, dichlorvos |
| Other ANS drugs | Acetylcholine, botulinum toxin, cocaine, dopamine, epinephrine, metanephrine, norepinephrine, saxitoxin, tetrodotoxin |
| Neurotransmitters: Parasympathetic NS | pre - ACH, post - ACH |
| Neurotransmitters: Sympathetic NS | pre - ACH, post - NE |
| Innervation of end organs: | some innervated by either PNS or SNS; some innervated by BOTH (PNS effect is usu opposite SNS); |
| Innervation of end organs: discharge pattern | PNS - "discrete" 1pre to 1 post; SNS - "diffuse" 1pre to many post |
| ANS Receptors: cholinergic | mucarinic, nicotinic |
| ANS Receptors: adrenergic | alpha, beta |
| Muscarinic Cholinergic Receptors: M1 | CNS, ANS ganglia |
| Muscarinic Cholinergic Receptors: M2 | heart |
| Muscarinic Cholinergic Receptors: M3 | smooth muscle, glands |
| Muscarinic Cholinergic Receptors: M4 and M5 | CNS |
| Nicotinic Cholinergic Receptors: Nn | CNS, ANS ganglia |
| Nicotinic Cholinergic Receptors: Nm | skeletal muscle |
| Neurotransmission | most NTs don't cross membranes; each binds to specific ptn receptors: Ion channels (change membrane pot/ion conc); Adenyl cyclase (inc ptn phosphorylation); DAG/IP3 (inc ptn phosph and intracellular Ca) |
| NT Release: Ca-dependent Exocytosis | AP --> depolarization --> enhanced Ca entry to nerve terminal; Ca enables fusion of storage granule ptns (synapsin/synaptobrevin) w/nerve terminal membrane followed by NT release |
| ACH Release - Quantal | Storage (one granule has <50K ACH molec); Release (ACH released from several hundred quanta) |
| Presynaptic Regulation of Transmitter Release: Autoreceptors | respond to NT released from its own nerve terminal; usu inhibits release of more NT |
| Presynaptic Regulation of Transmitter Release: Heteroreceptors | respond to NTs released from other nerve terminals or substances from nearby tissue or blood |
| Presynaptic Regulation of ACH Release: Dec ACH release from PNS - M2, M4 presynaptic receptors | stimulated by ACH released from PNS nerve terminals |
| Presynaptic Regulation of ACH Release: Dec ACH release from PNS - a2a, a2c presynaptic receptors | stimulated by NE released from SNS nerve terminals |
| Presynaptic Regulation of ACH Release: Inc ACH release from spinal nerves - Nn receptors | stimulated by ACH released from spinal nerves to skeletal muscle; prolongs NMJ fxn during prolonged high-frequency contraction of skeletal muscle |
| Stress Reaction: SNS in action - "Fight or Flight" | inc flow of oxygenated blood; inc skeletal muscle contractility; inc blood glucose; inc platelet aggregation; inc pupil diameter (mydriasis) |
| Stress Reaction: Increased flow of oxygenated blood - b2 | dilate bronchi and vessels to skeletal muscle |
| Stress Reaction: Increased flow of oxygenated blood - b1 | positive chronotropic (rate) and inotropic (force of contraction) cardiac effects |
| Stress Reaction: Increased flow of oxygenated blood - a1 | constrict arteries to skin, GI, kidney and shunt blood to skeletal muscles; contracts spleen to inc RBCs in blood |
| Stress Reaction: Increase skeletal muscle contractility - b2 | EPI increases rate and force of contraction |
| Stress Reaction: Increase/Maintain Blood Glucose - a1, b2 | increase glycogenolysis |
| Stress Reaction: Increase/Maintain Blood Glucose - b2 | increase glucagon secretion |
| Stress Reaction: Increase/Maintain Blood Glucose - a2 | decrease insulin secretion |
| Stress Reaction: Platelet aggregation - a2 | increases |
| Stress Reaction: eye - a1 | contracts radial muscle of iris ==> mydriasis |
| Stress Reaction: eye - b2 | relaxes ciliary muscle for far vision |
| Stress Reaction: sweat glands - a1 | increase activity |
| Stress Reaction: sweat glands - M3 | increases sympathetic cholinergic |
| Visual Accomodation - SNS | distant vision accomodation: relaxes ciliary body, tension on lens, flattens lens |
| Visual Accomodation - PNS | near vision accomodation; contract ciliary body, lessen tension on lens, thickens lens |
| Visual Accomodation - cycloplegia | loss of accomodation d/t antimuscarinic drugs (atropine) |
| Enteric Nervous System: myenteric and submucosal plexuses | contain interneurons w/transmitters ACH, NE, Substance P, enkephalins, vasoactive intestinal peptide (VIP); local reflexes maintain peristalsis/secretion; innervated by PNS, SNS and sensory nerves |
| Enteric Nervous System: ANS | modulates neural regulation |
| Enteric Nervous System: PNS | directly innervates smooth muscle and glands of gut |
| Enteric Nervous System: SNS | inhibits gut motility and secretions; synaps w/ PNS cells w/in intramural plexuses inhibits ACH release from PNS nerve terminals |
| Direct Acting: Muscarinic Agonists - Pilocarpine | Glaucoma |
| Direct Acting: Muscarinic Agonists - Carbachol | Glaucoma |
| Direct Acting: Muscarinic Agonists - Behanechol | postoperative ileus, megacolon, urinary retention |
| Indirect Acting: ACHE Inhibitors - Physostigmine | glaucoma |
| Indirect Acting: ACHE Inhibitors - Echothiophate | glaucoma |
| Indirect Acting: ACHE Inhibitors - Isoflurophate | glaucoma |
| Indirect Acting: ACHE Inhibitors - Decamerium | glaucoma, treats myasthenia gravis |
| Indirect Acting: ACHE Inhibitors - Edrophonium | diagnose myasthenia gravis; reverses NM blockade; supraventricular tachyarrhythmia |
| Indirect Acting: ACHE Inhibitors - Neostigmine | glaucoma, post-op ileus, megacolon, urinary retention, reverse NM blockade |
| Neurotransmission: Muscarinic Receptor Agonists | inc cGMP; inhibits cAMP activity; attenuate inc cAMP induced by EPI, NE; stimulates DAG and IP3 to inc phosphorylation and intracellular Ca |
| The Plan: Parasympathomimetic | Direct: Muscarinic receptor agonists; Indirect: Inhibits ACHI |
| The Plan: Parasympatholytic | Direct: Receptor antagonists; Indirect: Decrease ACH release |
| Parasympathomimetic Therapy Overview: Muscarinic Agonists | glaucoma, post-op ileus, congenital megacolon, urinary retention |
| Parasympathomimetic Therapy Overview: ACHE inhibitors | glaucoma, post-op ileus, congenital megacolon, urinary retention, diagnose/treat myasthenia gravis; reverse neuromuscular blockade; Alzheimer's disease |
| Parasympathetic Therapy Overview: Muscarinic Antagonists | antsecretory; examin retina/measure refraction; hypermotility of GI and urinary tract; urinary incontinence; IBS; COPD; Parkinson's Disease |
| Parasympathetic Therapy Overview: Ganglionic Blockers | hypertensive emergency |
| Parasympathomimetic Amines: adverse drug reactions (ADRs) | avoid IM or IV injections: hypotension (reflex tachycardia); miosis; hypersalivation/sweating; bronchoconstriction; GI discomfort; impaired cognition (pilocarpine) |
| Parasympathomimetic Amines: Contraindications | Asthma, CAD, bradycardia, peptic ulcer, GI/GU hypermotility or obstruction, COPD, HYPOtension |
| Parasympathomimetic Amines: Treatment of Glaucoma - Open Angle Primary | ocular angle is open; abnormal trabecular network impedes drainage of aqueous humor |
| Parasympathomimetic Amines: Treatment of Glaucoma - Open Angle Secondary | d/t inflammation, trauma, or ocular disease |
| Parasympathomimetic Amines: Treatment of Glaucoma - Mechanism and Caution | contract longitudinal ciliary muscle --> stretch/open trabecular network; Miosis --> iris moves away from ocular angle; Caution: Reduced accomodation |
| Parasympathomimetic Amines: Treatment of Glaucoma - Closed Angle | Medical emergency; lense position blocks access of aqueous humor to trabecular network; indication - short term prior to surgery; caution: Rx may inc IOP (miosis --> iris presses against lens and blocks anterior chamber) |
| Parasympathomimetic Amines: Pilocarpine, Pilocar, Pilopine HS Gel, Ocsert (time release); tertiary amine; lipophilic; pure muscarinic agonist | open-angle glaucoma - parasympathomimetic amine of choice; Xerostomia d/t radiation or Sjogren's syndrome (Cevimeline, Evoxac) |
| Parasympathomimetic Amines: Bethenechol (Urecholine) | relatively specific for M3 receptors of GI and GU; post-op urinary retention; GERD - inc LES pressure; Caution w/IM or IV injection --- circulatory collapse/cardiac arrest |
| Direct Acting Parasympathomimetic Amines: Muscarine alkaloids/Amanita muscaria ADRs | mushroom poisoning onset 15-30min; N&V, diarrhea; bronchial constriction; cutaneous vasodilation |
| Indirect Acting Parasymathomimetic Drugs: Reversible ACHE Inhibitors | broader use than muscarinic agonists; Reversible (Neostigmine, Prostigmin) and Irreversible (Organophosphates) |
| ACHE Inhibitor duration of action: Edrophonium | 5-15 min |
| ACHE Inhibitor duration of action: Neostigmine | 30min - 2hr |
| ACHE Inhibitor duration of action: Physostigmine | 30min - 2hr |
| ACHE Inhibitor duration of action: Pyridostigmine | 3 - 6hrs |
| ACHE Inhibitor duration of action: Ambenonium | 4 - 8hrs |
| ACHE Inhibitor duration of action: Demacarium | 4 - 6hrs |
| ACHE Inhibitor duration of action: Echothiophate | 100hrs |
| Indirect Acting Parasympathomimetic Drugs: Reversible ACHE Inhibitors - Neostigmine (prostigmin) | urinary retention (contract bladder wall/relax internal sphincter); Parylitic Ileus; Open-angle glaucoma; Myasthenia gravis (skeletal muscle weakness d/t dec nicotinic receptors at NMJ; ACHE inhibitors inc ACH to stim available receptors |
| Parasympathomimetic "Irreversible" ACHE Inhibitors: organophosphates | phosphorylated ACHE enzyme is extremely stable; restoration of normal ACH fxn requires synthesis of new ACHE molecules (days); good absorption across body membranes ==> widespread distribution thru body and CNS |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Echothiophate (phospholine) | open angle glaucoma (100hr duration) |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Diazinon, Malathion, Malaoxon, Parathion | insecticides |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Abuse | nerve gas (ricin, sarin, soman, tabun); symptoms occur w/in 6hrs w/50% inhibition; hypotension, miosis, bronchospasm, abdominal cramps, incontinence, arrhythmias, hypertension, respiratory paralysis, tremor, weakness, seizures, coma |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Treatment of Nicotinic Effects - Pralidoxime (2-PAM, Protopam) | regenerates ACHE - breaks ACHE-organophosphate bond; IV q 5-30min; repeat in 30min PRN; Rapid injection --> laryngospasm, muscle rigididy, weakness |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Aging | breaking one oxygen-phosphorous bond of inhibitor further strengthens phosphorous-enzyme bond |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Treatment of Muscarini Effects - Atropine generic | blocks muscarinic receptors; IV q 5-15min to dry bronchial secretions; repeat or constant IV infusion; questionable efficacy to treat CNS toxicity |
| Indirect Acting Parasympathomimetic "Irreversible" ACHE Inhibitors: Treatment of Seizures | benzodiazepines |
| Parasympatholytic Muscarinic Receptor Antagonist: Atropine Indications - adjunct to general anesthesia | reduce bronchial secretion; prevent vagal reflex d/t organ manipulation |
| Parasympatholytic Muscarinic Receptor Antagonist: Atropine Indications - Myocardial Infarction | prevent reflex bradycardia; AV block |
| Parasympatholytic Muscarinic Receptor Antagonist: Atropine Indications - Mushroom poisoning | some mushrooms contain muscarininc alkaloids |
| Parasympatholytic Muscarinic Receptor Antagonist: Atropine Indications - Ophthalmic Examination | ciliary paralysis, mydriasis - facilitates examination of fundus |
| Parasympatholytic Muscarinic Receptor Antagonist: Tolerodyne (Detrol), Oxybutynin (Ditropan) Indications - Urinary incontinence | relax urinary bladder wall; contract internal sphincter |
| Antinicotinic Decreased ACH Release - Botulinum toxin (Botox) | decreases ACH release from spinal nerves into NMJ, temporary paralysis of skeletal muscle |
| Antinicotinic Decreased ACH Release: Botulinum toxin (Botox) Indications - Cosmetic | facial wrinkles (red facial mm contraction); hyperhydrosis, blepharospasm; skeletal muscle spasticity; multiple sclerosis (bladder and bowel symptoms) |
| Neuromuscular Junction Blockers Non-Depolarizing: Curare (d-tubocurarine) Indications - Adjunct to general anesthesia | Reversible competitive blockade of nicotinic receptors of neuromuscular junction --> flaccid paralysis |
| Neuromuscular Junction Blockers Non-Depolarizing: Similar Drugs - Mivacurium (Mivacron) | short acting; 10-20min |
| Neuromuscular Junction Blockers Non-Depolarizing: Similar Drugs - Vecuronium (Norcuron) | intermediate acting; 20-35min |
| Neuromuscular Junction Blockers Non-Depolarizing: Similar Drugs - Doxacurium (Nuromax) | long acting; >35min |
| Neuromuscular Junction Blockers Depolarizing: Succinylcholine (Anectine) Indications - Adjunct to general anesthesia | persistent opening of nicotinic receptor channel --> prolonged depolarization of motor endplate --> loss of electrical excitability; duration ~5-10min |
| Indirect Acting ACE Inhibitors: Ambenonium | treats myasthenia gravis |
| Indirect Acting ACE Inhibitors: Pyridostigmine | Reverses NM blockade |
| ACHE Inhibitors: Role in Alzheimers | 40-90% dec in choline acetyltransferase in cortex/hippocampus b/f sx; correlation w/ dec ACH, mental status score & sx; Nerves passing thru plaques are damaged and have disrupted NTs; the axons project to cortex/hippocampus for memory/cognition |
| ACHE Inhibitors: Role in Alzheimers - IV physostigmine | significant improvement of visual recognition |
| ACHE Inhibitors: Role in Alzheimers - Butyl-cholinesterase | may have role in plaque development |
| Cholinergic role in Alzheimers - The Flaws | function of other NTs also decrease (seratonin, NE); cholinergic dysfunction may be a result not a cause of Alzheimers |
| ACHE Inhibitor Role in Alzheimers: Tacrine (Cognex) - additional MOA | blocks neuronal K channels prolonging APs to increase amount of ACH released |
| ACHE Inhibitor Role in Alzheimers: Tacrine (Cognex) - Indications | mild to moderate conditions; dose-related improvement of cognition and attention tasks; slow decline may occur |
| ACHE Inhibitor Role in Alzheimers: Tacrine (Cognex) - ADRs | rate limitins/decreased use; liver toxicity; N&V, loose stools, dizziness, HA; tolerance develops to peripehral cholinergic effects |
| ACHE Inhibitors Role in Alzheimers: Donepezil (Aricept) | selective for CNS ACHE; few effects on peripheral ACHE (less effect on GI pseudocholinesterase)!! Long half-life = once daily dosing; mild to moderate improvement of cognitive testing/caregiver impression scale; efficacy dec w/continued therapy |
| NMDA Antagonists Role in Alzheimers: Memanthine (Namenda) | dose-dependent blockade of glutamine receptors; efficacy reduces rate of clinical deterioration; ADRs - HA, dizziness (mild, reversible) |
| ACHE Inhibitor Role in Alzheimers: Rivastigmine (Exelon) | efficacy, ADRs similar to donepezil |
| ACHE Inhibitor Role in Alzheimers: Galantamine (Razadyne) | efficacy and ADRs similar to donepezil and rivastigmine |
| Adrenergic Receptor Typical Effects: alpha1 | stimulates |
| Adrenergic Receptor Typical Effects: alpha2 | inhibits |
| Adrenergic Receptor Typical Effects: beta1 | stimulates (heart) |
| Adrenergic Receptor Typical Effects: beta2 | inhibits (bronchi of lung; dilation) |
| Adrenergic Receptor Typical Effects: beta3 | stimulates lipolysis in fat cells (beta1 and beta2 have minor role) |
| Sympathomimetic: Direct acting | receptor agonist |
| Sympathomimetic: Indirect acting | increases synaptic NE |
| Sypatholytic: Direct acting | receptor antagonist |
| Sympatholytic: Indirect acting | decrease synaptic NE |
| Adrenergic Agonists: Structure/Activity Relationship: Non-catechol Amines (phenylephrine and amphetamine) | remove OH at benzene ring position 4; Less a and b receptor affinity than EPI; Poor substrates for MAO and COMT (won't be catalyzed as fast; last longer than NE); Oral absorption, long duration of action; Penetrates BBB (lipid soluble) |
| Adrenergic Agonists: Structure/Activity Relationship: Catecholamines (EPI, NE, Isoproterenol) | Agonist of a and b receptors (both OH needed for max binding); Do NOT cross BBB; Metabolized by neuronal MAO and COMTof liver/GI; Not orally active; Short duration; Readily oxidized (light/pH sensitive) |
| Adrenergic Agonists: Structure/Activity Relationship: alpha Carbon Substitution | poor substrates for MAO; prolongs duration of action of catecholamines and non-catecholamines |
| Adrenergic Agonists: Structure/Activity Relationship: beta OH | required for storage in nerve terminal granules |
| Adrenergic Agonists: Structure/Activity Relationship: Amine Nitrogen Substitution | beta receptor affinity increases as group on amine nitrogen increases in size (EPI > NE) |
| Adrenergic Agonists: Examples of Non-catecholamines | Amphetamine, Ephedrine, Dobutamine, Methyphenidate, Albuterol, Phenylephrine |
| Synthesis of Catecholamines | Tyrosine --> DOPA --> Dopamine --> NE --> EPI (bulkier amines stimulate beta receptors) |
| Cocaine | blocks reuptake of NE into nerve terminal |
| Alpha 2 receptors stimulated on nerve terminal has: | negative feedback on NE release |
| Radial m. of eye: SNS effect, adrenergic receptor | contracts (mydriasis); alpha1 |
| Circular m. of eye: PNS effect; cholinergic receptor | Contract (miosis); M3 |
| Trabecular network of eye: SNS Effect; Adrenergic Receptor | Increases outflow of aqueous humor; alpha2 |
| Trabecular Network of eye: PNS effect; Cholinergic Receptor | Increases outflow of aqueous humor; M3 |
| Ciliary Process (epithelium) of Eye: SNS Effect, Adrenergic Receptor | Increased synthesis of aqueous humor; Beta2 OR Decreases synthesis of aqueous humor; alpha2 |
| Lungs: SNS Effect, Adronergic Receptor | Dilates; beta2 |
| Lungs: PNS Effect; Cholinergic Receptor | Contract; M3 |
| Heart Rate: SNS Effect: Adrenergic Receptor | increases; beta1 |
| Heart Rate: PNS Effect: Cholinergic Receptor | Decreases; M2 |
| Heart Force: SNS Effect: Adrenergic Receptor | Increases; beta1 |
| Heart Force: PNS Effect: Cholinergic Receptor | Decreases; M2 |
| Blood Vessels: SNS Effect; Adrenergic Receptor | constrict; alpha1 |
| Coronary Arteries: SNS Effect; Adrenergic Receptor | dilate; inc work of heart increases synthesis of adenosine (vasodilator) |
| Coronary Arteries: PNS Effect; Cholinergic Receptor | Dilate; M2 |
| Blood Vessels in Skeletal Muscle: SNS Effect; Adrenergic Receptor | Dilate; beta2 |
| Skeletal Muscle Contractility: SNS Effect; Adrenergic Receptor | increases; beta2 |
| Spleen: SNS Effect: Adrenergic Receptor | contracts; alpha1 |
| Platelet aggregation: SNS effect; adrenergic receptor | increases; alpha2 |
| Apocrine sweat glands (stress): SNS effect; adrenergic receptor | increases; alpha1 |
| Sweat gland temperature regulation: SNS effect; Adrenergic Receptor | increases; M3 sympathetic cholinergic |
| Liver Glycongenolysis: SNS Effect; Adrenergic Receptor | Increases; alpha1, beta2 |
| Fat Cell Lipolysis: SNS Effect; Adrenergic Receptor | increases; beta3 (small role of b1/b2) |
| Pancreas Insulin secretion: SNS Effects; Adrenergic Receptor | Decreases; alpha2 OR Increases; beta2 |
| Pancreas Glucagon Secretion: SNS Effects; Adrenergic Receptor | Increases; beta |
| GI tract wall: SNS Effect; Adrenergic Receptor | relaxes; alpha2, beta2 |
| GI tract wall: PNS Effect; Cholinergic Receptor | contracts; M3 |
| GI tract secretion: PNS Effect; Cholinergic Receptor | Increases; M3 |
| Kidney Renin Secretion: SNS Effect; Adrenergic Receptor | increases; beta1 |
| Nasal, salivary, gastric secretory glands: SNS Effect; Adrenergic Receptor | decrease; alpha1 |
| Nasal, salivary, gastric secretory glands: PNS Effect; Cholinergic Receptor | Increases; M3 |
| Bladder Wall: SNS Effect; Adrenergic Receptor | relaxes; beta3 |
| Bladder wall: PNS effect; cholinergic receptor | contracts; m3 |
| Bladder internal sphincter: SNS effect; adrenergic receptor | contracts; alpha1 |
| Bladder internal sphincter: PNS effect; cholinergic receptor | relaxes; M3 |
| Ureter: SNS effect; adrenergic receptor | contracts; alpha1 |
| Ureter: PNS effect; cholinergic receptor | relaxes; M3 |
| Prostate capsule: SNS Effect; adrenergic receptor | contracts; alpha1 |
| Uterus (pregnant): SNS effect; adrenergic receptor | relaxes; beta2 |
| Uterus (pregnant); PNS effect; Cholinergic receptor | variable; M3 |
| Penile arteries: SNS effect; adrenergic receptor | contracts (detumescence); alpha1 |
| Penile arteries: PNS effect; cholinergic receptor | relax (erection); M3 |
| SNS Postganglionic Nerve Terminal: SNS Effect; Adrenergic Receptor | decrease NE release; alpha2 |
| SNS postganglionic nerve terminal: PNS Effect; cholinergic receptor | decreses NE release; M3 |
| alpha1 Receptor Effects | contract radial m. of iris (mydriasis); increases sweating (stress); constricts vasculature of skin (inc TPR/BP); contracts spleen/prostate capsule/penile aa/seminal vesicles/bladder&GI sphincters; dec nasal/salivary/gastric secretions |
| alpha2 Receptor Effects | inhibit NE release; inhibit insulin release; dec synthesis of aqueous humor; increase platelet aggregation |
| beta1 Receptor Effects | increase rate/force of myocardial contraction; increase renin secretion (inc blood vol); relaxes ciliary m. |
| beta2 Receptor Effects | inc synthesis of aqueous humor; dilate bronchi; relax GI wall/bladder wall/pregnant uterus; inc skeletal muslce & liver glycogenolysis; inc glucagon secretion; inc skeletal m contractility |
| Metabolic Effects of beta receptors: Glycogenolysis | skeletal muscle (b2); liver (b2, a1) |
| Metabolic Effects of b receptors: Lipolysis | fat cells: b3 (a1, b1, b2) |
| Epinephrine (adrenaline, epipen): non-selectice a/b agonist (a1, b1, b2) | vasoconstriction (skin), inc rate/contractility of heart, dilates bronchi; |
| Epinephrine (adrenalin, epipen): Cardiac Arrest | injected directly into heart for b1 effects |
| Epinephrine (adrenalin, epipen): Hypersensitivity/Anaphylaxis | antagonize vasodilation induced by histamine/leukotrienes (normalize permeability of venules); beta2 bronchodilation inhibits release of inflammatory mediators |
| Epinephrine (adrenalin, epipen): Adverse Drug Reactions | tachycardia, increased BP |
| Epinephrine (adrenalin, epipen): Topical Hemostasis | a1 vasoconstriction; also prolongs effect of local anesthetics |
| Norepinephrine (noradrenalin, levophed): a/b non-selective agonist (a1, b1) | vasoconstriction, positive cardiac chrono/inotropic effects (VERY little effect on b2 vasodilation) |
| Norepinephrine (noradrenalin, levophed): Indication | shock - counteracts hypotension |
| Norepinephrine (noradrenalin, levophed): Adverse Drug Reactions | bradycardia (dt baroreceptor vagal reflex); inceased BP |
| Phenylephrine (neo-synephrine) | a1-Selective Agonist |
| Phenylephrine (neo-synephrine): Nasal decongestant | constricts nasal vasculature, shrinks swollen membranes |
| Phenylephrine (neo-synephrine): hypotension | antagonizes hypotension associated w/anesthesia |
| Phenylephrine (neo-synephrine): Mydriasis | contracts radial m. of iris |
| Epinephrine | a1, a2, b1, b2: slight inc in HR; slight drop in peripheral resistance; systolic inc/diastolic dec slightly |
| Norepinephrine | a1, a2, b1; baroreceptor reflex; HR slows; great inc in peripheral resistance; systolic rises/diastolic inc slightly |
| Isoproterenol | b1, b2; HR rises; big drop in peripheral resistance b/c no alpha constriction; systolic slight inc/diastolic drops |
| Miosis drugs | contraction of circular muscle fibers in iris; stimulated and iris goes towards center of pupil |
| Mydriasis drugs | alpha1 are dilator fibers; pulls iris muscle back to get dilation of pupil |
| Oxymetazoline (afrin): a1 selective agonist | nasal decongestant, OTC |
| Metaraminol (aramine): a1 selective agonist | shock-induced hypotension; prescritpion |
| Clonidine (catapres): a2 selective agonist | stimulates a2 presynaptic receptors to dec NE release; used for withdrawal from dependece-producing drugs (nicotine and opiate withdrawal inc NE release) |
| Clonidine (catapres): Hypertension | stimulates a2 receptors of vasomotor ctr to decreases SNS discharge and increase PNS discharge; Decreases HR, CO, and TPR |
| Clonidine (catapres): Precautions During Therapy | orthostatic hypotension (stimulationof presynaptic a2 receptors decreases NE release causing vasodilation) |
| Clonidine (catapres): Precautions about Abrupt Cessation | hypertension (decreased stimulation of presynaptic a2 receptors increases NE release)...must wean pt off drug |
| Clonidine (catapres): Drug Interactions | tricyclic antidepressants (TCA) block a1 receptors ==> block anti-HT effects of clonidine |
| a-Methyl Dopa (aldomet): a2a-Selective Agonist | metabolized to a-methyl NE |
| a-Methyl Dopa (aldomet): Hypertension | dt clonidine-like CNS MOA; safe use in pregnancy |
| a-Methyl Dopa (aldomet): Adverse Drug Reactions | limit use; hepatotoxicity; hemolytic anemia |
| Dobutamine (dobutrex): b1-Selective Agonist MOA | (-) isomer (a1 agonist + weak b1 agonist) and (+) isomer (a1 antagonist + potent b1 agonist) ==> NET EFFECT |
| Dobutamine (dobutrex): Inotropic effect > Chronotropic effect | increases contractility and CO; lack of b2 effect (less vasodilation/less activation of baroreceptor reflex; LESS TACHYCARDIA) |
| Dobutamine (dobutrex): Caution | tolerance w/prolonged use |
| Dobutamine (dobutrex): Indications | cardigenic shock, refractory CHF, acute cardiac compensation (IV infusion; 2min onset), Myocardial Infarction |
| Albuterol (proventil): Asthma | bronchodilation, anti-inflammatory, inhibit release of inflammatory mediators from mast cells, increase mucus clearance by cilia |
| Albuterol (proventil): Caution (downregulation/desensitization) | agonist of b receptors; activates adenyl cyclase, inc cAMP, activates phosphokinase A, phosphorylates b receptor protein = Reduced Effect of Agonist! |
| b2 Selective Agonist Inhalers: Albuterol | Onset (5min); Duration (4-6hr); acute bronchospasm, prevents exercise-induced asthma |
| b2 Selective Agonist Inhalers: Bitolterol (tornalate) | Onset (2-4min); Duration (4-6hrs) |
| b2 Selective Agonist Inhalers: Salmeterol (severent) | Onset (10-20min); Duration (>12hrs); maintenance (mild to moderate asthma); nocturnal symptoms; w/inhaled corticosteroid reduces need to inc steroid dose |
| Albuterol (proventil): Adverse Drug Reactions | tremor, tachycardia (b2 = 25% of cardiac b); arrhythmias with high dose; death??? |
| Ritodrine (yutopar): b2 selective agonist | Indication for arresting premature labor |
| Ritodrine (yutopar): Adverse Drug Reactions | cardiac stimulation, hypotension, neonatal hypoglycemia |
| Dopamine (intropin): dopamine agonist MOA | "renal dose" <2ug/kg/min; stimulates D2 presynaptic and D1 postsynaptic receptors; diates renal/mesenteric/coronary vessels |
| Dopamine (intropin): b1 agonist | medium dose (2-10ug/kg/min); positive inotropic effect |
| Dopamine (inotropin); a1 agonist | High dose (10ug/kg/min); vasoconstriction |
| Dopamine (intropin): indications | shock a/w low CO and compromised renal fxn; CHF; acute renal failure |
| Fenoldopam (corlopam): Dopamine D1 Agonist | dilates renal, mesenteric, and coronary aa; reaches steady state serum level in 20min; (also weak a2 agonist) |
| Fenoldopam (corlopam): Indication | short term (up to 48hrs) Rx for severe hypertension |
| Fenoldopam (corlopam): Adverse Drug Reactions | dose-related hypotension; tachycardia (risk of exacerbated CHF); headache, flushing |
| Amphetamine (Dexedrine, Dextrostat): Increases Transmitter Release - Peripheral Effects | Increases release and inhibits uptake of NE |
| Amphetamine (Dexedrine, Dextrostat): Increases Transmitter Release - CNS Effects | increases release and inhibits uptake of NE in limbic system (d-isomer > l-isomer) as well as DA and Seratonin possibly by stimulating inhibitory pathways leading to frontal cortex and limbic system) |
| Amphetamine (Dexedrine, Dextrostat): Indications | Narcolepsy (65-85% efficacy); ADHD (impulsivity, hyperactivity, inability to focus, hypofxn of frontal cortex/limbic system?) |
| Methampthetamine (Desoxyn, "speed"): Increase transmitter release | compared to amphetamine there is a greater CNS effect and less severe peripheral effect |
| Amphetamine (dexedrine) and Methamphetamine (Desoxyn "speed"): Adverse Drug Reactions | anorexia, paranoia, aggressive behavior, arrhythmias, subarachnoid hemorrhage, convulsions, vomiting/diarrhea, euphoria, hypertension, ischemic stroke, coma |
| Methamphetamine (Desoxyn, Speed): Long-term abuse | loss of DA uptake; gray matter structure abnormalities, impaired memory and verbal learning, motor slowing, phsycosis |
| Methamphetamine "speed": Treatment | HT(a-antagonist/Na nitroprusside); NH4Cl (acidify urine to enhance clearance); Anxiety (benzodiazepine); Phychosis (haloperidol may inc meth serum concentration) |
| MDMA "Ecstasy" (d- and dl-amphetamine, Adderall): Increases Transmitter Release MOA in CNS | Releases and inhibits reuptake of seratonin; (3, 4-methylendedioxymethamphetamine) |
| MDMA "Ecstasy" (d- and dl-amphetamine, Adderall): Adverse Drug Reactions | LSD-like; hallucinations, perceptual disorders |
| Cocaine "crack": Indications | local anesthetic blockade of neuronal Na+ binding sites to prevent depolarization |
| Cocaine "crack": Adverse Drug Reactions | CNS effects dt inhibition of NE, DA, and serotonin reuptake; Tachyphylaxis (25mg line - 9g) |
| d- and dl-amphetamine (Adderall): Adverse Drug Reactions | this drug is abused; sudden cardiac death in children (family Hx of SVT, near drowning, cardiac structure abnormalities, heat exhaustion, heart attack); FDA prohibits use in cardiac defect pts; suspended in Canada |
| Methylphenidate (Ritalin, Concerta): Increases Transmitter Release | mild amphetamine, less CNS stimulation, appetite suppression, tachycardia, phsychosis; 3-5hr duration, tolerance develops |
| Atomoxetine (strattera): Inhibits NE uptake | selective inhibitor of NE uptake, not CNS stimulant; slower onset; second line Rx for non-responders/intolerant to CNS stimulants |
| Atomoxetine (strattera): compared to amphetamine | not a CNS stimulant, less "hill and valley" effects; less efficacy? |
| Atomoxetine (strattera): Adverse Drug Reactions | usu results in discontinuation (nausea, sedation, irritability, temper tantrums) |
| Atomoxetine (strattera): Suicidal Ideation? | FDA public health advisory issued 9/05; call for mfg to issue patient medicaiton guide for parents |
| Pemoline (cylert): Increase Transmitter Release | efficacy similar to methylphenidate |
| Pemoline (cylert): Adverse Drug Reactions | **Severe Liver Toxicity; CNS problems similar to methylpenidate; less cardiovascular problems |
| Pseudophedrine (Sudafed): Inc NE release/a1b1 agonist | increases release of NE, weak agonist of a1 and b1 receptors |
| Pseudophedrine (Sudafed): Indications | nasal decongestant, urinary incontinence (a1 contracts internal sphincter) |
| Pseudophedrine (Sudafed): Warning | similar to methamphetamine; must by capsules behind pharmacy counter now so sales are logged to prevent misuse |
| Ephedrine (ephedra, ma-huong): Increase NE release/a1b1 agonist: Indications | nasal decongestant, appetite suppression |
| Ephedrine (ephedra, ma-huong): Adverse Drug Reactions | seizure, troke, MI; withdrawn from market by FDA |
| Monoamine Oxidase (MAO) Inhibitors | located in nerve terminals, liver, GI mucosa, platelets; regulates degradation of catecholamines and serotonin in CNS/periphery |
| Hepatic MAO | metabolizes circulating monoamines such as indirect-acting sympathomimetic amines (dietary tyramine (tyrosine?)) |
| MAO Inhibitors: MAO-A | role in adrenergic nerve terminals (ANS, CNS); preferentially deaminates NE, EPI and serotonin, Inhibited by Clorgyline |
| MAO Inhibitors: MAO-B | found in serotonin and histaminergic nerve terminals; deaminates Phenethylamine; Inhibited by Selegiline (eldepryl) |
| MAO-A and MAO-B | metabolize tyramine and DA; Inhibited by Phenelzine (Nardil) and Tranylcypromine (Partate) |
| MAO Inhibition Onset | occurs w/in few days but onset of clinical efficacy is several weeks; down-regulation of adrenergic and/or serotonin receptors |
| MAO Inhibitors: Caution | Irreversible Inhibition: it takes several weeks to regenerate MAO; 2wk washout of MAOI prior to start of sympathomimetic Rx (ex: many OTC cold products); Risk of fatal intracranial bleeds!! |
| MAO Inhibitors: Indications | treatment of resistant depression (2nd or 3rd line Rx); MAOI-A is more effective than MAOI-B for treating major depression (clinical efficacy occurs w/80% inhibition to enhance availabe dopamine) |
| MAO Inhibitors: Parkinsons Disease | degeneration of DA neurons that project from S. nigra to basal ganglia and striatum; DA deficit corrected by Levodopa; efficacy "wears off" after several years; Adjunct to L-dopa to increase available DA |
| MAO Inhibitors: Other Indications | phobias, social anxiety (phenylzine 77% effic; seligiline 32% effic); Refractory migraine, Panic disorder? (poorly designed trials/adequate dose/duration?) |
| MAO Inhibitors: Adverse Drug Reactions | Hepatotoxicity (Pheylzine-Nardil >> Tranylcypromine-Parnate); Hyperprolactinema; postural hypotension (mc); anti-ACh; sexual dysfunction-dose related |
| MAO Inhibitors: Drug Interactions | Meperidine (demerol); Dextromethorphan, Tricyclic antidepressants, SSRIs, L-tryptophan (inc serotonin synth); Sumatriptan (CNS 5-HT agonist) |
| MAO Inhibitors: Serotonin Syndrome | HT, shivering, diaphoresis, muscle rigidity, fever, agitation, hallucinations |
| MAO Inhibitors: "Cheese Reaction" | dietary tyramine increases release of catecholamine and 5-HT causing a HYPERTENSIVE Crisis (10mg - HT, 25mg - HTCrisis) |
| Selegiline (eldepryl): MAO Inhibitor | selective inhibitor of MAO-B; less risk for "cheese rxn;" dietary tyramine is metabolized by MAO-A (less tyramine to release NE and 5-HT) |
| Selegiline (eldepryl): MOA | metabolized to L-amphetamine + L-methamphetamine; Neuroprotection; prevents peroxide formation a/w oxidative deamination of DA? |
| a-Methyltyrosine (desmer): Decreases NE synthesis | inhibits tyrosine dydroxylase (rate limiting); depletes catecholamines in SNS nerve terminals, adrenal medulla, and CNS |
| a-Methyltyrosine (desmer): Indications | pheochromocytoma (tumor of adrenal medulla that secretes excessive EPI and NE |
| a-Methyltyrosine (desmer): Adverse Drug Reactions | Nasal stuffiness, diarrhea, impotence, hallucinations, depression, Parkinsonism (no NE to constrict a1 in nasal mucosa); exaggerated cholinergics = diarrhea (adronergics slow it down but they're blocked); no dopamine = hypercholinergic = muscle rigidity |
| Reserpine (serpasil): decrease NE storage | irriversibly blocks CCA uptake into nerve terminal storage granules (several day duration) |
| Reserpine (serpasil): Indications | hypertension (outdated) |
| Guanethidine (ismelin): inhibit NE release | displaces NE from storage granules = gradual long-term depletion; Irreversible damage of nerve terminal = sympathectomy |
| Guanethidine (ismelin): Indication | severe HT (outdated) vasodilation increases venous capacity |
| Guanethidine (ismelin): Adverse Drug Reactions | similar to a-methyltyrosine and reserpine |
| Phenoxybenzamine (dibenzyline): non-selective irreversible a-receptor agonist | a1 = a2; 48hr turnover time |
| Phenoxybenzamine (dibenzyline): Indications | 1. Pheochromocytoma (long-term for inoperable cases; 1-3wks pre-op to control BP; concomitant Rx w/a-methyltyrosine and/or b-blocker; 2. Autonomic hyperreflexia dt spinal cord transection |
| Phentolamine (regitine): Non-selective Reversible a-Receptor Agonist | a1 = a2; indicated for: 1. Raynaud's disease (arterial injection/infusion; improves finger blood flow/digital pulse vol/forearm flow; reduces vasospasm); 2. Pheochromocytoma; 3. Erectile Dysfxn (intracavernosal injection) |
| Phentolamine (regitine): Adverse Drug Reactions | IV: severe tachycardia/arrhythmias/myocardial ischemia; vasodilation activates baroreceptor reflex/inc SNS activity; blockade of a2 presyn receptors inc NE release; 2. PO: tachycardia, nasal congestion; 3. Inhibits ejaculation |
| Prazosin (minipress): Selective Reversible a-Receptor Antagonist | a1 >>>>a2; 1. Benign prostatic hypertrophy (blocks a1a receptors [70% of receptors] relaxes prostate capsule, intern sphincter of bladder/urethra); 2. Hypertension (not monotherapy; block arteriole/vein a1b to dec venous return, TPR, CO/BP) |
| Prazosin (minipress): MOA acute and long-terem | 1. Acute: baroreceptor reflex inc HR + renin (Na/H2O retention); 2. Long-term: HR and renin return to normal; Lack of a2 blockade = no increased release of NE |
| Prazosin (minipress): Adverse Drug Reactions | 1. "first dose effect" Orthostatic Hypotension (OH) dt blockade of 1b receptors; possible CNS effect to dec SNS outflow; 2. 50% incidence of concomitant diuretic Rx (a1b blockade, CNS effect?) |
| Prazosin (minipress): "First Dose Effect" | OH after first dose (90min onset) - 1% incidence at >2mg; low dose 1mg at HS; HS dose titration; May also occur during rapid dose increase (after first few days of Rx or resumption of Rx after few days w/o drug) |
| Terozasin (hytrin): Selective Reversible a-Receptor Antagonist | indicated for: Hypertension and Benign Prostatic Hypertrophy |
| Terozasin (hytrin): Adverse Drug Reactions | First dose effect; slow titration schedule (days 1-3 = 1mg HS; days 4-14 = 2mg HS; wks 2-6 = 5mg HS; wks 7+ = 10mg HS) |
| Tamsulosin (Flomax): Selective Reversible a-Receptor Antagonist | indicated for: Benign Prostatic Hypertrophy; selective block of a1a receptors (inhibits contraction of prostate vascular smooth muscle; less affinity for a1b receptors in arterioles/veins so less OH (less need for dose titration); not studied for HT |
| Tamsulosin (Flomax): Adverse Drug Reactions | Priapism (prolnged and painful erection) |
| Tamsulosin (flomax): Advantages | initial Rx at lowest maintenance dose; dose anytime during day, no dose titration (shorter ~2wk onset of peak effect); OK to add to selective anti-hypertensives (altenolol, furosemide, enalapril, nifedipine) |
| Alfuzosin (uroxotral): Selective Reversible a-Receptor Antagonists | a Tamsulosin "me too" drug |
| Doxazosin (cardura): Selective Reversible a-Receptor Antagonists | indicated for: BPH and HT (effective as MONOTHERAPHY or w/diuretics, b-blockers, Ca-channel blockers, angiotensin-converting enzyme (ACE) inhibitors); exhibits "First Dose Effect" |
| Pharmokinetics of Selective Reversible a-Receptor Antagonists: Prozasin | Serum half-life = 2-3hrs; 2-3 dose/day |
| Pharmokinetics of Selective Reversible a-Receptor Antagonists: Alfuzosin | Serum half-life = 3-5hrs; 1dose/day |
| Pharmokinetics of Selective Reversible a-Receptor Antagonists: Terazosin | Serum half-life = 9-12hrs; 1dose/day |
| Pharmokinetics of Selective Reversible a-Receptor Antagonists: Tamsulosin | Serum half-life = 9-15hrs; 1dose/day |
| Pharmokinetics of Selective Reversible a-Receptor Antagonists: Doxazosin | Serum half-life = 22hrs; 1dose/day |
| b-Receptor Antagonists (Blockers) | compounds vary receptor selectivity, local anesthetic action, lipid solubility, elimination half-life; Partial b-agonist action (intrinsic sympathomimetic activity (ISA); Acebutolol, Carteolol, Penbutolol, Pindolol; less drop of rest-HR/CO/periph flow) |
| b-Receptor Antagonists (blockers): Pharmokinetics | First-pass metabolism (Propranolol, metoprolol) pt/dose variability; Long half-life, Renal excretion (dose adjust); Shorter half-life (1/day usu effective) |
| Sympatholytic b-Receptor Antagonists: 1st Generation Non-Selective | Propranolol (Inderal) |
| Sympatholytic b-Receptor Antagonists: 2nd Generation Selective b1-Cardioselective beta blockers | Acebutolol, Altenolol, Betaxolol, Bisoprolol, Esmolol, Metoprolol |
| Sympatholytic b-Receptor Antagonists: 3rd Generation Non-selective b-blockade + a-blockade (vasodilation) | Carvedilol (coreg), Labetolol (normodyne) |
| Acebutolol | b1-selective; partial agonist, local anesthetic |
| Atenolol | b1-selective |
| Betaxolol | b1-selective; slight anesthetic |
| Bisoprolol | b1-selective |
| Carteolol | not selective, partial agonist |
| Carvedilol | non-selective (also causes a1 adrenoceptor blockade) |
| Celiprolol | b1-selective; partial agonist effects at b2 receptors |
| Esmolol | b1-selective; |
| Labetalol | non-selective; partial agonist, local anesthetic (also causes a1 adenoceptor blockade) |
| Metoprolol | b1-selective; local anesthetic |
| Nadolol | non-selective |
| Penbutolol | non-selective; partial agonist |
| Pindolol | non-selective; partial agonist; local anesthetic |
| Propranolol | non-selective; local anesthetic |
| Sotalol | non-selective |
| Timolol | non-selective |
| b-Receptor Antagonists: b1-cardioselective | b1>b2: heart and kidney (vs. b2>b1: lungs/liver/pancreas/arterioles); less likely to provoke broncospasm/vasoconstriction; safer for asthmatics, COPD, peripheral vascular dx, diabetes; preferred in ischemic heart disease to prevent second MI |
| b-Receptor Antagonists: Effects on Heart | At Rest: modest reduction of HR and force of contraction; Stress Rxn: attenuate typical positive inotropic and chronotropic effects |
| b-Receptor Antagonists: Effects on Eye | reduce formation of aqueous humor |
| b-Receptor Antagonists: Effects on Kidney | antagonize release of renin |
| b-Receptor Antagonists: Member stabilizing ("Quinidine-like" Effect) | blocks Na channels of nerve, heart, skeletal muscle; dose-dependent |
| b-Receptor Antagonists: Effects on Serum Lipids | Non-selective (reduce HDL, increase LDL and TGs); b1-Selective (improve lipid profile of dyslipidemic pts) |
| b-Receptor Antagonists: Adverse Drug Reactions | Reduce insulin secretion mostly in insulin-dependent diabetics (hyperglycemia, hampers recovery from hypoglycemia, masks warning signs of hypoglycemia/hyperthyroidism (tachycardia)); Exacerbates Hypoglycemia (inc SNS tone, unopposed a1 vasoconstriction) |
| b-Receptor Antagonists: Adverse Drug Reactions | Hypotension, Cardiac Failure (usu high dose; a/w prior LV dysfxn, neg inotropics); Bradycardia, heart block, Exacerbate bronchospasm in asthma/COPD; Exacerbate Raynaud's disease; Erectile Dysfxn (dec flow to corpora); CNS (depression, fatigue, no libido) |
| b-Receptor Antagonists: Warnings - Exercise | attenuates the following: cardiac stimulation, bronchodilation, glycogenolysis and lipolysis |
| b-Receptor Antagonists: Warnings - Pheochromocytoma | may result in paradoxical hypertension |
| b-Receptor Antagonists: Warnings - Diabetics | prevents tachycardia seen in hypoglycemia; reduced insulin response to hyperglycemia; may need to adjust antidiabetic Rx |
| b-Receptor Antagonists: Warnings - Abrupt Cessation of Rx | For pts predisposed to myocardial ischemia (MI, arrhythmia, death, inc sensitivity of b-receptors to EPI and NE; failure to dec physical activity); Uncompromised pts (tachycardia, inc sweating, malaise); **Taper dose over 2wks |
| b-Receptor Antagonists: Contraindications | Bronchial asthma (non-selective, lacking ISA); Cardiac Failure (use w/caution in pts w/well-compensated cardiac failure); Cardiogenic shock; Severe bradycardia; Severe prolonged hypotension |
| b-Receptor Antagonists: Indications | Hypertension, Migraine, Anxiety, Hyperthyroidism, Myocardial Infarction, Angina, Heart failure |
| b-Receptor Antagonists: MOAs to lower BP via Inhibition of Renin Release | Pts w/low renin respond; drugs w/little effect on plasma renin lowers BP (pindolol) |
| b-Receptor Antagonists: MOAs to lower BP in CNS | CNS concentration of Propranolol > Atenolol (have similar anti-HT effects); drugs w/poor CNS penetration lower BP |
| b-Receptor Antagonists: MOAs to lower BP and Cardiac Output Reduction | similar CO decrease in responders and non-responders |
| b-Receptor Antagonists: MOAs to lower BP via inhibition of NE | Presynaptic Inhibition of NE Release (b-agonists inc release) - role is unclear |
| b-Receptor Antagonists: MOAs to lower BP | different cardioselectivity, intrinsic sympathomimetic activity (ISA), membrane stabilizing effects (similar antiHT effects) |
| b-Receptor Antagonists: Most Logical MOA | long-term Rx reduces peripheral resistance (inc NO, a1 antagonist, block Ca-channels, b2 agonist, antioxidant, open K-channels; Combined effect of reduced CO and reduced peripheral resistance |
| Labetolol (normodyne, trandate): b1, b2, a1 Receptor Antagonist | indicated for: Preclampsia HT (IV); HT of pregnancy (doesn't aggravate peripheral vascular disease as much as pure b-blockers); HT emergency (decreases peripheral vascular resistance w/no effect on HR or CO) |
| b-Receptor Antagonists: Migraine Prophylaxis | unknown MOA; most widely used (atenolol, metoprolol, nadolol, propranolol); drugs w/ISA are ineffective |
| b-Receptor Antagonists: Alcohol Withdrawal and Social Anxiety | blocks peripheral SNS effects |
| b-Receptor Antagonists: Anxiety | useful for pts w/palpitations or tremor; for non-responders to benzodiazepine (ex: Valium); Typical onset = 1wk (take ahead of time); Taper to avoid rebound anxiety |
| b-Receptor Antagonists: Hyperthyroidism | palpitations, anxiety, tremor, heat intolerance; inhibits conversion of T4 to T3; minor effect unrelated to b-blockade |
| b-Receptor Antagonists: Role in Ischemic Heart Disease | dec HR and contractility, slight BP dec myocardial O2 demand; countered slightly by inc ventricular vol and ejection time; Net Effect: Reduced Myocardial O2 Demand; (a1 stimulation in presence of b-blockade may constrict coronary aa) |
| b-Receptor Antagonists: Role in Ischemic Heart Disease - b-blocker of choice | no evidence to ID a b-blocker; Cardioselectives may be preferred in pts w/COPD, asthma or intermittent claudication; Labetolol = possible less coronary artery constriction (useful in pts w/little LV reserve) |
| b-Receptor Antagonists: MI | recuce ventricular arrhythmias, recurrent ischemia and re-infarction; reduced workload dt reduced HR, systolic BP, and myocardial contractility |
| b-Receptor Antagonists: Acute MI | n = 16,000; Atenolol IV, oral; 15% reduction in vascular mortality OR n = 6,000; Metoprolol 13% reduction in mortality in 1 month |
| b-Receptor Antagonists: Post MI | short term dose of various b-blockers after MI are more beneficial; n = 1,884 pts for 12-33 mo, Timolol 39% red mortality and 28% red re-infarct; OR n = 3,837 for 27 months Propranolol 26% red mortality; |
| b-Receptor Antagonists: Angina | reduces frequency and severity of exertional angina |
| b-Receptor Antagonists: Angina Pectoris | neg inotropic/chronotropic effects; red myocardial O2 demand; inc diastolic coronary perfusion time; Atenolol (reduced hospitalization for angina, need for revascularlization, death); Chronic/stable w/preserved LV fxn (question red in mortality; MI Hx pt) |
| b-Receptor Antagonists: Perioperative | CABG after MI; 1yr mortality red from 12 to 4%; Non-cardiac surgery in pts w/coronary risk factors; fewer perioperative CV events |
| b-Receptor Antagonists: Heart Failure | Bisoprolol w/pts with LVEF 34% red in mortality; significantly fewer CV deaths |
| b-Receptor Antagonists: Heart Failure | Metoprolol extended release in pts w/LV ejection fraction; red mortality, sudden death and death dt worsening CHF |
| b1-Cardioselective Receptor Antagonists | dose-dependent (high dose also blocks b2); patient-specific |
| Esmolol (brevibloc injection): b1-Cardioselective Receptor Antagonist | 10-20min duration; hemodynamics return to baseline in 30min; Indicated for: Supraventricular tachycardia, Arrhythmias a/w thyrotoxicosis; Intra-operative/Post-op tachycardia and/or hypertension; Myocardial Ischemia |
| Esmolol (brevibloc injection): Drug Interactions | Succinylcholine (prolong duration of NM blockade by 5-8min); Digoxin (inc digoxin serum level by 20%); Morphine (inc esmolol serum level by 45%) |
| Pindolol (visken): Mixed b antagonist + partial b agonist | desirable in asthmatics who cannot tolerate other b-blockers; desirable in pts w/low resting HR |
| Labetolol (normodyne, trandate): b1, b2, a1 Receptor Antagonist | dec BP w/o reflex tachycardia and w/o red in HR; BP is lowered more in standing than supine position; OH First Dose Effect can occur (usu w/in 2-4hrs of large initial dose or on change of dose) |
| Labetolol (normodyne, trandate): Indications | Oral (Hypertension); IV for hospitalized pts (severe HT dt risk of OH, pt must be supine during injection; must be able to tolerate upright posture b/f ambulating) |
| Carvedilol (coreg): mixed b + a1 antagonist | compared to other b-blockers: produces more hypotension and dizziness; possible greater anti-hypertensive effect |
Created by:
bscaryp